Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$11.12 USD

11.12
286,409

+0.42 (3.93%)

Updated May 21, 2024 04:00 PM ET

After-Market: $11.11 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Will Agenus Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Agenus.

Are You Looking for a Top Momentum Pick? Why Agenus (AGEN) is a Great Choice

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 13.16% and 27.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs

Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agenus' (AGEN) Pipeline Progression on Track Amid Competition

Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.

Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

Agenus (AGEN) Surpasses Q1 Earnings Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.

Gilead & Galapagos Announce Positive Data on Arthritis Drug

Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.

Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.